In recent years, the development of new systemic treatment modalities such as immune check point inhibitors, and BRAF plus MEK inhibitors provides an alternative for patients suffering from melanoma brain metastases by virtue of their intracranial efficacy44. Here, MAP2K7 is linked to melanoma.